Liftstream is an executive search recruitment company in the life sciences sector
PTC Therapeutics appoints Chief Medical Officer and communicates CHMP conditional decision
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Ariad, Ataluren, Chief Medical Officer, CHMP, DMD, Duchenne, Duchenne Muscular Dystrophy, EMA, europe, GSK, Iclusig, investors, MAA, market authorisation application, Murad Husain, oncology, parents, patients, phase III clinical trial, Prosensa, PTC Therapeutics, Rober J. Spiegel, Sarepta, USA, VP Global Regulatory Affairs
Leave a comment
PTC Therapeutics opts for conditional approach in Duchenne
Authored by Paul Foster
Posted in Orphan Drugs and Rare Diseases
Tagged Allan Jacobson, AstraZeneca, Ataluren, celgene, Cystic Fibrosis, DMD, DNA, Duchenne Muscular Dystrophy, EMA, FDA, Genzyme, Gilead, Liftstream Rare Disease Day, MAA, Marketing Authorisation Application, Merck, Orphan Drug, Pfizer, PTC Therapeutics, Rare Disease, rare disease day, RDD13, Stuart W. Peltz
Leave a comment
Roche Snags Phase III Agromegaly Drug from Chiasma
Roche have announced they have acquired the rights to a phase III oral Agromegaly drug Octreolin from, Israeli biotech, Chiasma. Agromegaly is a rare progressive disease caused by the over production of growth hormone resulting in severe disfigurement. Agromegaly is estimated to occur in approximately 6 in every 100,000 people.
Posted in M&A Finance and Funding
Tagged Abingworth, Agromegaly, Chiasma, EMA, FDA, MAA, MPM Capital, Octreolin, Orphan Drug, Phase III, Roche, Series D
Leave a comment